C
C. Lance Cowey
Researcher at Texas Oncology
Publications - 40
Citations - 7103
C. Lance Cowey is an academic researcher from Texas Oncology. The author has contributed to research in topics: Ipilimumab & Nivolumab. The author has an hindex of 19, co-authored 39 publications receiving 4940 citations. Previous affiliations of C. Lance Cowey include The Royal Marsden NHS Foundation Trust & Baylor University Medical Center.
Papers
More filters
Journal ArticleDOI
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Jedd D. Wolchok,Vanna Chiarion-Sileni,Rene Gonzalez,Piotr Rutkowski,Jean-Jacques Grob,C. Lance Cowey,Christopher D. Lao,John Wagstaff,Dirk Schadendorf,Pier Francesco Ferrucci,Michael Smylie,Reinhard Dummer,Andrew F. Hill,David Hogg,John B. A. G. Haanen,Matteo S. Carlino,Oliver Bechter,Michele Maio,Ivan Marquez-Rodas,Massimo Guidoboni,Grant A. McArthur,Céleste Lebbé,Paolo A. Ascierto,Georgina V. Long,Jonathan Cebon,Jeffrey A. Sosman,Michael A. Postow,Margaret K. Callahan,Dana Walker,Linda Rollin,Rafia Bhore,F. Stephen Hodi,James Larkin,James Larkin +33 more
TL;DR: Among patients with advanced melanoma, significantly longer overall survival occurred with combination therapy with nivolumab plus ipilimumab or with n ivolumAB alone than with ipil optimumab alone.
Journal ArticleDOI
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
Jeffrey S. Weber,Mario Mandalà,Michele Del Vecchio,Helen Gogas,Ana Arance,C. Lance Cowey,Stéphane Dalle,Michael Schenker,Vanna Chiarion-Sileni,Ivan Marquez-Rodas,Jean-Jacques Grob,Marcus O. Butler,Mark R. Middleton,Michele Maio,Victoria Atkinson,Paola Queirolo,Rene Gonzalez,Ragini R. Kudchadkar,Michael Smylie,Nicolas Meyer,Laurent Mortier,Michael B. Atkins,Georgina V. Long,Shailender Bhatia,Céleste Lebbé,Piotr Rutkowski,Kenji Yokota,Naoya Yamazaki,Tae M. Kim,Veerle de Pril,J Sabater,Anila Qureshi,James Larkin,Paolo A. Ascierto +33 more
TL;DR: Among patients undergoing resection of stage IIIB, IIIC, or IV melanoma, adjuvant therapy with nivolumab resulted in significantly longer recurrence‐free survival and a lower rate of grade 3 or 4 adverse events than adjuant therapy with ipilimumab.
Journal ArticleDOI
Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials.
Dirk Schadendorf,Jedd D. Wolchok,F. Stephen Hodi,Vanna Chiarion-Sileni,Rene Gonzalez,Piotr Rutkowski,Jean-Jacques Grob,C. Lance Cowey,Christopher D. Lao,Jason Chesney,Caroline Robert,Kenneth F. Grossmann,David F. McDermott,Dana Walker,Rafia Bhore,James Larkin,Michael A. Postow,Michael A. Postow +17 more
TL;DR: Efficacy outcomes seemed similar between patients who discontinued nivolumab plus ipilimumab treatment because of AEs during the induction phase and those who did not discontinue because of aEs, suggesting that many patients may continue to derive benefit from combination therapy even after discontinuation.
Journal ArticleDOI
Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial.
Paolo A. Ascierto,Michele Del Vecchio,Mario Mandalà,Helen Gogas,Ana Arance,Stéphane Dalle,C. Lance Cowey,Michael Schenker,Jean-Jacques Grob,Vanna Chiarion-Sileni,Ivan Marquez-Rodas,Marcus O. Butler,Michele Maio,Mark R. Middleton,Luis de la Cruz-Merino,Petr Arenberger,Victoria Atkinson,Andrew F. Hill,Leslie A. Fecher,Michael Millward,Nikhil I. Khushalani,Paola Queirolo,Maurice Lobo,Veerle de Pril,John T. Loffredo,James Larkin,Jeffrey S. Weber +26 more
TL;DR: The results presented in this report reflect the 4-year update of the ongoing study with a database lock date of Jan 30, 2020 and show sustained recurrence-free survival benefit versus ipilimumab.
Journal ArticleDOI
Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma
Jedd D. Wolchok,Vanna Chiarion-Sileni,Rene Gonzalez,Jean-Jacques Grob,Piotr Rutkowski,Christopher D. Lao,C. Lance Cowey,Dirk Schadendorf,John Wagstaff,Reinhard Dummer,Pier Francesco Ferrucci,Michael Smylie,Marcus O. Butler,Andrew F. Hill,Ivan Marquez-Rodas,John B. A. G. Haanen,Massimo Guidoboni,Michele Maio,Patrick Schöffski,Matteo S. Carlino,Céleste Lebbé,Grant A. McArthur,Paolo A. Ascierto,Gregory A. Daniels,Georgina V. Long,Tuba Bas,Corey Ritchings,James Larkin,F. Stephen Hodi +28 more
TL;DR: In the phase III CheckMate 067 trial, durable clinical benefit was demonstrated previously with nivolumab plus ipilimumab and nivolaumab alone versus IPILimumab as discussed by the authors.